methyl 2-methyl-1 H-benzimidazole-4-carboxylate | 208772-14-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: methyl 2-methyl-1 H-benzimidazole-4-carboxylate
• 英文别名: Methyl 2-methyl-1H-benzo[d]imidazole-4-carboxylate；methyl 2-methyl-1H-benzimidazole-4-carboxylate
• CAS: 208772-14-9
• 化学式: C₁₀H₁₀N₂O₂
• 分子量: 190.202
• InChiKey: NYWNVKDIUUSMIT-UHFFFAOYSA-N

物化性质

• 沸点：
  404.4±18.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  55
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-methyl-1 H-benzimidazole-4-carboxylate 、 溴丙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 methyl 2-methyl-1-propyl-1 H-benzimidazole-4-carboxylate
  参考文献：
  名称：

  Benzamide derivatives having a vasopressin antagonistic activity

  摘要：

  这项发明涉及新的苯甲酰胺衍生物，它们具有抗血管加压素活性，并由通式（I）表示： 其中R1是可选地被低级烷氧基取代的芳基等， R2是低级烷基等， R3是氢等， A是NH等， E是 等， X是—CH═CH—，—CH═N—或S，而 Y是稠合杂环基等， 以及它们的药用可接受盐，其制备过程以及包含它们的药物组合物。

  公开号：

  US06207693B1

文献信息

• [EN] PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS<br/>[FR] DICARBOXAMIDE DE PYRIDINONE UTILISÉ COMME INHIBITEUR DE BROMODOMAINE
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017037116A1

  公开（公告）日：2017-03-09

  The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.

  本发明涉及式(I)的化合物及其盐，含有这种化合物的药物组合物，以及它们在治疗中的应用。
• 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS
  申请人：OM Pharma SA

  公开号：EP3878837A1

  公开（公告）日：2021-09-15

  The invention provides hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascular, ophthalmologic, fibrotic, metabolic and gastro-intestinal disorders, neuroinflammatory and neurodegenerative diseases, neoplasms and cancer associated disorders, hormone related diseases and immunological disorders resulting from viral and bacterial infectious diseases and complications thereof. wherein: Ra, Rb = H, acyl or aryl alkyl; R1 = COOR4, (CH2)nCOOR4, SO3H, (CH2)nSO3H or CONH-R10; R2 and R3 = H or R5, with the proviso that when one of R2 and R3 is R5, the other is H; R4 = H, alkyl or aryl alkyl; R5 = R6, R7 or R8; R6 = CONH-R9, CONHCOR9, CONH(CH2)n- R9, CONHCH(COOR4)(CH2)k R9 or heteroaryl-R9; k = 0-4; R7 = optionally substituted benzoheteroaryl ; R8 = (CH 2)mX(CH2)p R9; X = O, S, SO2, NH, NAc or N(CH2)q R9; R9 = optionally substituted aryl, heteroaryl or cycloalkyl ; R10 = optionally substituted aryl or heteroaryl ; n, m, p and q = independently 1-4.

  该发明提供了公式（I）的氢醌衍生物，制备方法，以及治疗和/或预防例如自身免疫、免疫学、风湿学、血管学、眼科学、纤维化、代谢和胃肠道疾病、神经炎症和神经退行性疾病、肿瘤和癌症相关疾病、激素相关疾病以及由病毒和细菌感染疾病及其并发症引起的免疫疾病的药物组合物和治疗方法。其中：Ra、Rb = H、酰基或芳基烷基；R1 = COOR4、（CH2）nCOOR4、SO3H、（ ）nSO3H或CONH-R10；R2和R3 = H或R5，但当R2和R3中的一个为R5时，另一个为H；R4 = H、烷基或芳基烷基；R5 = R6、R7或R8；R6 = CONH-R9、CONHCOR9、CONH（ ）n-R9、CONHCH（COOR4）（ ）kR9或杂环芳基-R9；k = 0-4；R7 = 可选取代的苯杂环芳基；R8 =（ ）mX（ ）pR9；X = O、S、SO2、NH、NAc或N（ ）qR9；R9 = 可选取代的芳基、杂环芳基或环烷基；R10 = 可选取代的芳基或杂环芳基；n、m、p和q = 独立地为1-4。
• Benzimidazole derivatives and their use as protein kinases inhibitors
  申请人：Berdini Valerio

  公开号：US20070135477A1

  公开（公告）日：2007-06-14

  The invention provides compounds of the formula (1): The compounds have activity against cyclin depdenent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.

  该发明提供了式（1）的化合物： 这些化合物具有对环素依赖性激酶、糖原合成酶激酶和Auroa激酶的活性，因此可用于治疗癌症和病毒性疾病。
• AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS WITH PYRIDINE RING AND HETEROCYCLIC COMPONENTS
  申请人：Herpin Timothy F.

  公开号：US20080275090A1

  公开（公告）日：2008-11-06

  The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型的氨基苯并咪唑及其类似物，它们是选择性抑制人类P2Y1受体的抑制剂。本发明还提供了各种药物组合物和方法，用于治疗对P2Y1受体活性调节敏感的疾病。
• Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
  申请人：Berdini Valerio

  公开号：US20080312223A1

  公开（公告）日：2008-12-18

  The invention provides a compound of the formula (I): or a salt, N-oxide, tautomer or solvate thereof, wherein X is CR 5 or N; each of Q 1 and Q 2 is a carbon atom; Q 3 is selected from S and CH; Q 4 is selected from CR 2 and S; provided that one of Q 3 and Q 4 is S and the other of Q 3 and Q 4 is not S; wherein when Q 3 is S, there is a double bond between Q 1 and Q 4 and a double bond between Q 2 and the adjacent ring nitrogen atom N; and when Q 4 is S, there is a double bond between Q 1 and Q 2 , and a double bond between Q 3 and the adjacent ring nitrogen atom N; A is a bond or —(CH 2 ) m —(B) n —; B is C═O, NR 8 (C═O) or O(C═O) wherein R 1 is hydrogen or C1_4 hydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R o is hydrogen or, together with NR g when present, forms a group —(CH 2 ) p — wherein p is 2 to 4; R 1 is hydrogen, a carbocyclic or heterocyclic group having from 3 to 12 ring members, or an optionally substituted C 1-8 hydrocarbyl group; R 2 is hydrogen, halogen, methoxy, or a C 1-4 hydrocarbyl group optionally substituted by halogen, hydroxyl or methoxy; R 3 and R 4 together with the carbon atoms to which they are attached form an optionally substituted fused carbocyclic or heterocyclic ring having from 5 to 7 ring members of which up to 3 can be heteroatoms selected from N, O and S; and R 5 is hydrogen, a group R 2 or a group R 10 wherein R 10 is as defined in the claims. The compounds have activity as inhibitors of cyclin dependent kinases, glycogen synthase kinases and Aurora kinases.

  本发明提供一种化合物，其化学式为（I）或其盐，N-氧化物，互变异构体或溶剂化物，其中X为CR5或N; Q1和Q2中的每一个都是碳原子; Q3从S和CH中选择; Q4从CR2和S中选择; 假设Q3和Q4中的一个是S，而另一个不是S; 当Q3为S时，Q1和Q4之间有一个双键，Q2和相邻的环氮原子N之间有一个双键; 当Q4为S时，Q1和Q2之间有一个双键，并且Q3和相邻的环氮原子N之间有一个双键; A是键或-(CH2)m-(B)n-; B为C═O，NR8（C═O）或O（C═O），其中R1为氢或C1_4烃基，可选择地被羟基或C1-4烷氧基取代; m为0、1或2; n为0或1; Ro为氢或与NRg一起形成一个群体-( )p-，其中p为2至4; R1为氢，具有3至12个环成员的碳环或杂环基，或可选择地被取代的C1-8烃基基团; R2为氢、卤素、甲氧基或可选择地被卤素、羟基或甲氧基取代的C1-4烃基基团; R3和R4与它们所连接的碳原子一起形成一个可选择地取代的融合碳环或杂环环，其具有5至7个环成员，其中最多可有3个异原子，选择自N、O和S; R5为氢、R2基团或R10基团，其中R10如权利要求所定义。该化合物具有作为细胞周期依赖性激酶、糖原合成酶激酶和极化子激酶的抑制剂的活性。